Skip to main content
. 2019 Nov 29;3:20. doi: 10.1186/s41824-019-0066-2

Fig. 53.

Fig. 53

68Ga-DOTA peptide, staging NET of the pancreas, comparison with FDG. Clinical history: 68 y.o. man with moderately differentiated multi-metastatic NET of pancreas (Ki67 8%). PET/CT findings: 68Ga-DOTANOC PET/CT shows intense pathologic uptake of somatostatin receptor analogue by the known pancreatic tumour, as well as in lymph nodes, multiple liver lesions, and previously unknown bone lesions (a). FDG-PET/CT confirms pathologic uptake of the tracer in pancreas and lymph nodes and in some of the known liver and bone lesions (b)